To investigate whether transgenic expression of PFKFB2 resulted in altered GC susceptibility, we treated the above T-ALL cell lines with 10-7M dexamethasone in the presence and absence of doxycycline (i.e., with and without transgenic PFKFB2 induction) and analyzed the extent of apoptosis (as measured by FACS analysis of propidium iodide incorporation) at various time points (Figure 3). The gene discussed is PFKFB2; the disease is acute lymphoblastic leukemia.